References
Feng J, Wang L, Yang X, Chen Q, Cheng X. Pretreatment pan-immune-inflammation value (PIV) in predicting therapeutic response and clinical outcomes of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2024;31:272–83.
Baba Y, Nakagawa S, Toihata T, et al. Pan-immune-inflammation value and prognosis in patients with esophageal cancer. Ann Surg Open. 2022;3:e113.
Song K, Fei S, Li B, Tian J. Application of preoperative pan-immno-inflammatory values in clinicopathological features and prognosis evaluation of esophageal cancer. Mod Dig Interv. 2022;27:834–9.
Feng J, Wang L, Yang X, Chen Q, Cheng X. Clinical utility of preoperative pan-immune-inflammation value (PIV) for prognostication in patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2023;123:110805.
Qi WX, Wang X, Li C, et al. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: an analysis from a prospective cohort. Thorac Cancer. 2023;14:1556–66.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shen, Y., Chen, L. & Che, G. Could Pretreatment Pan‑Immune‑Inflammation Value Predict Survival in Esophageal Cancer?. Ann Surg Oncol 31, 3868–3869 (2024). https://doi.org/10.1245/s10434-024-15100-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-024-15100-7